Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03358290 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Akros Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03358290 is a Phase 2 study that was terminated before completion, run by Akros Pharma. The registered enrollment target is 13 participants.
The verdict
NCT03358290, a Phase 2 study, was terminated before completion, sponsored by Akros Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG JTE-051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-11-10 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03358290
The ClinicalTrials.gov registry entry for NCT03358290 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03358290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03358290 about?
NCT03358290 is a clinical study titled "Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis". Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT03358290?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2017-11-10. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT03358290?
The interventions under investigation include: Placebo (DRUG), JTE-051 (DRUG).
Who is sponsoring clinical trial NCT03358290?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.